GLP-1 Medications and Mental Health: What New Research Shows About Depression, Anxiety, and Mood
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
If you are on a GLP-1 medication and have noticed that your mood feels a little lighter, you are not imagining it. A major study of nearly 96,000 people found that semaglutide, the active ingredient in Wegovy and Ozempic, was linked to a 42% drop in psychiatric hospitalizations and a 44% lower risk of worsening depression in people who already had mental health conditions (The Lancet Psychiatry). That is a big deal, and it is worth understanding what it means and what it does not.
Who This Helps
This article is for you if you take a GLP-1 medication and have wondered whether it might be affecting your mood. It is also for you if you saw those early scary headlines about suicidal thoughts and GLP-1s and have been carrying that worry around. And it is for anyone with depression, anxiety, or other mental health concerns who wants to understand how these medications interact with the emotional side of health. GLP Winner helps you compare providers and costs for FDA-approved GLP-1 medications so you can make decisions that feel right for your whole self.
What Did the Biggest Study Find?
In March 2026, researchers published results from one of the largest studies ever done on GLP-1 medications and mental health. They used Swedish national health records to follow 95,490 adults who already had depression or anxiety. About 22,480 of those people were prescribed a GLP-1 medication. Around 60% were women, and the average age was about 51 (The Lancet Psychiatry).
What makes this study special is how it was designed. Instead of comparing one group of people to another group, the researchers compared each person to themselves. They looked at how people did during the months they were on a GLP-1 medication versus the months they were not. That design helps control for a lot of the differences between people that can muddy the results.
Here is what they found:
- Overall risk of worsening mental health dropped by 42%
- Risk of worsening depression dropped by 44%
- Risk of worsening anxiety dropped by 38%
- Risk of worsening substance use disorder dropped by 47%
- Psychiatric hospital visits and sick leave for mental health dropped by 42%
Semaglutide, which is the active ingredient in Wegovy and Ozempic, showed the strongest effects. Liraglutide, an older GLP-1 medication, showed more modest benefits at about 18% (The Lancet Psychiatry). If you are curious how these medications compare in terms of pricing and which providers offer them, GLP Winner's comparison tools can help you see the landscape.
What This Means for You
A 42% drop in psychiatric care is a striking number. It suggests something real is happening. But this was an observational study, not a clinical trial designed to test mental health benefits. It tells us there is a strong link, but it cannot prove that semaglutide caused the improvement. If you live with depression or anxiety and are considering a GLP-1 medication, this research is worth bringing up with your doctor. It adds to a growing body of evidence that these medications may be doing more than just helping with weight.
What About Those Scary Suicidal Thoughts Headlines?
You may remember the headlines. A few years ago, early safety reports raised a red flag about a possible link between GLP-1 medications and suicidal thoughts. The FDA took it seriously and added warnings to the labels of several GLP-1 products while they investigated (FDA).
In January 2026, the FDA finished that review. It was thorough. They looked at 91 placebo-controlled clinical trials involving 107,910 patients. The conclusion: no increased risk of suicidal thoughts or actions. And no increased risk of other psychiatric side effects like anxiety, depression, irritability, or psychosis (FDA).
The FDA then requested that the suicidal ideation warning be removed from GLP-1 labels entirely. A separate analysis of 2.2 million healthcare claims confirmed the finding: no increased risk of intentional self-harm in GLP-1 users compared to people on a different class of diabetes medication (Pharmacy Times).
The FDA did note one important caveat. Because suicidal thoughts are rare events overall, they cannot completely rule out that a very small risk might exist somewhere in the data. But across more than 100,000 patients, the evidence did not support keeping the warning.
If you have been carrying worry about this, hopefully that puts it in perspective. GLP Winner tracks FDA safety updates so you always have the latest information.
Why Would a Weight Loss Medication Affect Your Mood?
This part is genuinely fascinating. GLP-1 stands for glucagon-like peptide-1, a hormone your body makes naturally. GLP-1 medications like Wegovy and Mounjaro work by activating GLP-1 receptors, which is the medical term for the docking stations in your body that this hormone connects to.
Here is the interesting part. Those receptors are not just in your gut and pancreas. They are also in several areas of your brain that control mood, motivation, and how you experience reward. Your amygdala, which helps process emotions. Your hippocampus, which handles memory and stress, and your ventral tegmental area, which is part of your dopamine system (Journal of Neuropsychiatry).
Recent research suggests these medications may be doing several things in the brain:
- Reducing brain inflammation, which has been linked to depression (PMC)
- Influencing dopamine and serotonin activity, two brain chemicals closely connected to mood (Frontiers in Pharmacology)
- In animal studies, promoting the growth of new brain cells in areas tied to stress and memory (PMC)
Weight loss itself can also improve mood by reducing inflammation and improving metabolic health. So the mental health benefits people experience likely come from a combination of the medication's direct effects on the brain and the overall improvements in physical health (Nature Mental Health).
What About Alcohol and Addiction?
One of the more surprising findings in recent GLP-1 research is that these medications may affect cravings for things beyond food. The Swedish study found a 47% lower risk of worsening substance use disorder during GLP-1 use (The Lancet Psychiatry).
A separate study at Virginia Tech found that GLP-1 medications slowed stomach emptying, which delayed alcohol absorption. People in the study reported feeling significantly less intoxicated even though they drank the same amount (Virginia Tech News).
Dr. Carolina Haass-Koffler, a researcher at Brown University, described this as a potential turning point in addiction care. She explained that GLP-1 medications appear to reduce dopamine-driven cravings by acting on the brain's reward system (Brown University).
Clinical trials are now underway to test GLP-1 medications specifically for alcohol use disorder. The Endocrine Society has noted that these drugs show promise for both alcohol and drug addiction, though more research is needed (Endocrine Society).
If you have noticed a change in your drinking habits or cravings since starting a GLP-1, you are not alone. This is an area where science is actively catching up to what many patients are already experiencing. GLP Winner covers this kind of emerging research as it develops.
What Researchers Still Do Not Know
The findings are encouraging, but researchers are honest about what they cannot say yet:
- The largest studies are observational. They show a strong link, but they cannot prove cause and effect. Randomized trials designed to test mental health outcomes specifically have not been completed (Nature Mental Health)
- Early clinical trials for Wegovy and Zepbound excluded people with depression. Ozempic trials did not measure mental health outcomes. That creates a gap in what we know about people with pre-existing mental health conditions (Psychiatric Times)
- It is unclear how much of the mood improvement comes from the medication versus the weight loss versus the better physical health that often comes along with treatment
- Most studies cover one to two years. We do not have long-term data yet
- There is limited research on how GLP-1 medications interact with common psychiatric drugs like antidepressants or mood stabilizers
These gaps matter. The research is promising, but GLP-1 medications are not currently prescribed for depression or anxiety. If you have mental health concerns, bringing this evidence to both your prescriber and your mental health provider is the best way to make it part of your overall care plan.
What This Means for You
If your mood has improved since starting a GLP-1, the science suggests there are real reasons for that. Your brain has GLP-1 receptors, and these medications appear to influence mood in ways researchers are just beginning to understand. At the same time, a GLP-1 is not a replacement for therapy, antidepressants, or other mental health treatments. It may become part of the picture eventually, but right now these findings are still being confirmed. GLP Winner can help you find a provider who looks at the whole picture, not just the number on the scale.
Final Takeaway
The story of GLP-1 medications and mental health is one of the most important things happening in this space right now. A year ago, the headlines were scary. Today, the data is pointing toward something much more hopeful.
The FDA has removed the suicidal ideation warning after reviewing more than 100,000 patients. The largest observational study we have shows real improvements in depression, anxiety, and even addiction. And scientists are finding biological reasons why it all makes sense.
This does not mean GLP-1s are a cure for anything. The science is early, and there is still a lot we do not know. But the direction of the evidence is encouraging, and it is absolutely worth discussing with your doctor.
Your health is more than a number on a scale. If a GLP-1 medication is helping you feel better in ways you did not expect, that is a conversation worth having.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
New research links GLP-1 medications to reduced addiction risk. See what the WashU and JAMA studies found and what clinical trials are underway.
FDA review finds no increased suicide risk with GLP-1 medications and is asking for related label warnings to be removed.
Learn which risks are real, which are exaggerated, and what most people actually experience over time.
Curated by
